SEARCH

SEARCH BY CITATION

References

  • 1
    Kikkawa F, Matsuzawa K, Arii Y, Kawai M, Kobayashi I, Nakashima N, Mizutani S. Randomized trial of cisplatin and carboplatin versus cisplatin, vinblastine and bleomycin in ovarian cancer. Gynecol Obstet Invest 2000; 50: 26974.
  • 2
    Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999; 72: 27887.
  • 3
    Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a southwest oncology group and gynecologic oncology group trial. J Clin Oncol 2003; 21: 24605.
  • 4
    McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 16.
  • 5
    Sanderink GJ, Artur Y, Siest G. Human aminopeptidases: a review of the literature. J Clin Chem Clin Biochem 1988; 26: 795807.
  • 6
    Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood 1993; 82: 105270.
  • 7
    Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 1994; 39: 23042.
  • 8
    Koch AE, Burrows JC, Skoutelis A, Marder R, Domer PH, Anderson B, Leibovich SJ. Monoclonal antibodies detect monocyte/macrophage activation and differentiation antigens and identify functionally distinct subpopulations of human rheumatoid synovial tissue macrophages. Am J Pathol 1991; 138: 16573.
  • 9
    Santos AN, Langner J, Herrmann M, Riemann D. Aminopeptidase N/CD13 is directly linked to signal transduction pathways in monocytes. Cell Immunol 2000; 201: 2232.
  • 10
    Kido A, Krueger S, Haeckel C, Roessner A. Possible contribution of aminopeptidase N (APN/CD13) to invasive potential enhanced by interleukin-6 and soluble interleukin-6 receptor in human osteosarcoma cell lines. Clin Exp Metastasis 1999; 17: 85763.
  • 11
    Fujii H, Nakajima M, Saiki I, Yoneda J, Azuma I, Tsuruo T. Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin Exp Metastasis 1995; 13: 33744.
  • 12
    Saiki I, Fujii H, Yoneda J, Abe F, Nakajima M, Tsuruo T, Azuma I. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 1993; 54: 13743.
  • 13
    Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60: 7227.
  • 14
    Mishima Y, Matsumoto-Mishima Y, Terui Y, Katsuyama M, Yamada M, Mori M, Ishizaka Y, Ikeda K, Watanabe J, Mizunuma N, Hayasawa H, Hatake K. Leukemic cell-surface CD13/aminopeptidase N and resistance to apoptosis mediated by endothelial cells. J Natl Cancer Inst 2002; 94: 10208.
  • 15
    Kajiyama H, Shibata K, Terauchi M, Morita T, Ino K, Mizutani S, Kikkawa F. Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo. Clin Cancer Res 2005; 11: 1798808.
  • 16
    Kajiyama H, Kikkawa F, Khin E, Shibata K, Ino K, Mizutani S. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res 2003; 63: 227883.
  • 17
    Inoi K, Goto S, Nomura S, Isobe K, Nawa A, Okamoto T, Tomoda Y. Aminopeptidase inhibitor ubenimex (bestatin) inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity. Anticancer Res 1995; 15: 20817.
  • 18
    Bauvois B, Dauzonne D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev 2006; 26: 88130.
  • 19
    Ishii K, Usui S, Sugimura Y, Yamamoto H, Yoshikawa K, Hirano K. Inhibition of aminopeptidase N (AP-N) and urokinase-type plasminogen activator (uPA) by zinc suppresses the invasion activity in human urological cancer cells. Biol Pharm Bull 2001; 24: 22630.
  • 20
    Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994; 5 ( Suppl 6): S3S6.
  • 21
    Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000; 88: 261928.
  • 22
    Blagosklonny MV. Unwinding the loop of Bcl-2 phosphorylation. Leukemia 2001; 15: 86974.
  • 23
    Lee LF, Li G, Templeton DJ, Ting JP. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 1998; 273: 2825360.
  • 24
    Meikrantz W, Schlegel R. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J Biol Chem 1996; 271: 102059.
  • 25
    Taxman DJ, MacKeigan JP, Clements C, Bergstralh DT, Ting JP. Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor. Cancer Res 2003; 63: 5095104.
  • 26
    Lee JT,Jr, Steelman LS, McCubrey JA. Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 2004; 64: 8397404.
  • 27
    Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot (Tokyo) 1976; 29: 979.
  • 28
    Ishizuka M, Sato J, Sugiyama Y, Takeuchi T, Umezawa H. Mitogenic effect of bestatin on lymphocytes. J Antibiot (Tokyo) 1980; 33: 65362.
  • 29
    Muller WE, Schuster DK, Zahn RK, Maidhof A, Leyhausen G, Falke D, Koren R, Umezawa H. Properties and specificity of binding sites for the immunomodulator bestatin on the surface of mammalian cells. Int J Immunopharmacol 1982; 4: 393400.
  • 30
    Kehlen A, Lendeckel U, Dralle H, Langner J, Hoang-Vu C. Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res 2003; 63: 85006.
  • 31
    Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, Yamaoka Y, Miyake M. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 2002; 122: 37686.
  • 32
    Ishii K, Usui S, Sugimura Y, Yoshida S, Hioki T, Tatematsu M, Yamamoto H, Hirano K. Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 2001; 92: 4954.
  • 33
    Hirano T, Kizaki M, Kato K, Abe F, Masuda N, Umezawa K. Enhancement of sensitivity by bestatin of acute promyelocytic leukemia NB4 cells to all-trans retinoic acid. Leuk Res 2002; 26: 1097103.
  • 34
    Lendeckel U, Arndt M, Frank K, Wex T, Ansorge S. Role of alanyl aminopeptidase in growth and function of human T cells (review). Int J Mol Med 1999; 4: 1727.
  • 35
    Chang YW, Chen SC, Cheng EC, Ko YP, Lin YC, Kao YR, Tsay YG, Yang PC, Wu CW, Roffler SR. CD13 (aminopeptidase N) can associate with tumor-associated antigen L6 and enhance the motility of human lung cancer cells. Int J Cancer 2005; 116: 24352.
  • 36
    Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H, Miyake M. Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res 2003; 9: 15038.
  • 37
    van Hensbergen Y, Broxterman HJ, Rana S, van Diest PJ, Duyndam MC, Hoekman K, Pinedo HM, Boven E. Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts. Clin Cancer Res 2004; 10: 118091.
  • 38
    Ichinose Y, Genka K, Koike T, Kato H, Watanabe Y, Mori T, Iioka S, Sakuma A, Ohta M. Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J Natl Cancer Inst 2003; 95: 60510.